$45 Neuropathy Relief Package (reg. $450) > SCHEDULE NOW < Click Here to
$45 Neuropathy Relief Package (reg. $450) > SCHEDULE NOW < Click Here to
$45 Neuropathy Relief Package (reg. $450) > SCHEDULE NOW < Click Here to
$45 Neuropathy Relief Package (reg. $450) > SCHEDULE NOW < Click Here to
Percutaneous Peripheral Nerve Stimulation in Chemotherapy-Induced Neuropathy: A Case Report
Reports (MDPI)
2025 Aug 1;8(3):133. doi: 10.3390/reports8030133
Author
Sara Mogedano-Cruz , Carlos Romero-Morales , Mónica de la Cueva-Reguera , Kristin L Campbell , Pablo Herrero
Editor: Toshio Hattori
Author Information
1Department of Physiotherapy, Faculty of Medicine, Health and Sports, European University of Madrid, Villaviciosa de Odón, 28670 Madrid, Spain; carlos.romero@universidadeuropea.es (C.R.-M.); monica.delacueva@universidadeuropea.es (M.d.l.C.-R.)
2Department of Physical Therapy, Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada; kristin.campbell@ubc.ca
3Institute for Health Research Aragon, Faculty of Health Sciences, University of Zaragoza, 50009 Zaragoza, Spain; pherrero@unizar.es
Correspondence: sara.mogedano@universidadeuropea.es
Roles
Toshio Hattori: Academic Editor
Article notes
Received 2025 Jul 9; Revised 2025 Jul 24; Accepted 2025 Jul 25; Collection date 2025 Sep.
Copyright and License information
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
PMC Copyright notice
PMCID: PMC12372149 PMID: 40843875
Abstract
Background and Clinical Significance
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and limiting complication of oncological treatment, particularly in patients receiving oxaliplatin. Its onset can significantly affect the quality of life and compromise the continuity of the antineoplastic therapy. Due to the limited efficacy of available pharmacological therapies, percutaneous electrical nerve stimulation (PENS) has been proposed as a non-invasive alternative for symptom management.
Case presentation
We report the case of a 75-year-old woman with colorectal adenocarcinoma who developed CIPN following oxaliplatin administration. She underwent a 12-week course of PENS targeting the median nerve, with weekly sessions conducted without interruption of chemotherapy and without adverse effects. The patient showed progressive improvement in neurosensory symptoms, as measured by the EORTC QLQ-CIPN20 questionnaire. Quantitative sensory testing revealed normalization of thermal and vibratory sensitivity and improved mechanical detection thresholds. The cumulative oxaliplatin dose was maintained throughout treatment.
Conclusions
PENS may offer an effective and safe therapeutic option for managing CIPN, enabling symptom control without compromising oncological treatment. This case supports the need for controlled clinical trials to confirm efficacy and establish standardized protocols.
Keywords:
chemotherapy-induced peripheral neuropathy, percutaneous electrical nerve stimulation, oxaliplatin, neuropathic pain, colon cancer